REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION

This adverse event was reported 55 times

These drugs are most commonly taken by patients reporting REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION:

# Drug Count
0 CISPLATIN 21
1 CAPECITABINE 19
2 DOCETAXEL 18
3 DOCETAXEL ANHYDROUS 18
4 BEVACIZUMAB 16
5 ATEZOLIZUMAB 15
6 OXALIPLATIN 12
7 PEMBROLIZUMAB 12
8 LENVATINIB 7
9 CARBOPLATIN 6
See all common drugs associated with REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION

REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PENPULIMAB 1 0.0102
1 PLATINUM 1 0.0019
2 FRUQUINTINIB 2 0.0005
3 ATEZOLIZUMAB 15 0.0004
4 REGORAFENIB 4 0.0003
5 CISPLATIN 21 0.0003
6 DOCETAXEL 18 0.0003
7 DOCETAXEL ANHYDROUS 18 0.0003
8 SORAFENIB 5 0.0002
9 LENVATINIB 7 0.0002
See all drugs enriched for association with REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION